ADAPT Naproxen Signal “Not Sufficiently Compelling” To Halt Trial – Speaker
This article was originally published in The Tan Sheet
Executive Summary
The halting of the NIH-sponsored ADAPT trial, which suggested that naproxen may be linked to an elevated cardiovascular risk, was due more to external factors and safety concerns surrounding the COX-2 class than the study data themselves
You may also be interested in...
Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands